The incidence of thyroid cancer (TC) has increased worldwide over the past four decades.
TC is divided into three main histological types: differentiated (papillary and follicular TC) …

Importance Approximately 43 720 new cases of thyroid carcinoma are expected to be
diagnosed in 2023 in the US. Five-year relative survival is approximately 98.5%. This review …

Background Selpercatinib, a highly selective, potent RET inhibitor, has shown efficacy in
advanced RET-mutant medullary thyroid cancer in a phase 1–2 trial, but its efficacy as …

Differentiated thyroid carcinomas is associated with an excellent prognosis. The treatment of
choice for differentiated thyroid carcinoma is surgery, followed by radioactive iodine ablation …

Background RET mutations occur in 70% of medullary thyroid cancers, and RET fusions
occur rarely in other thyroid cancers. In patients with RET-altered thyroid cancers, the …

Since the discovery of the RET receptor tyrosine kinase in 1985, alterations of this protein
have been found in diverse thyroid cancer subtypes. RET gene rearrangements are …

Background The development of systemic treatment options leveraging the molecular
landscape of advanced thyroid cancer is a burgeoning field. This is a multidisciplinary …

Medullary thyroid carcinoma (MTC) is a rare neuroendocrine malignancy derived from
parafollicular cells (C cells) of the thyroid. Here we presented a comprehensive multi-omics …

The knowledge on thyroid cancer biology has grown over the past decade. Thus, diagnostic
and therapeutic strategies to manage thyroid cancer are rapidly evolving. With new insights …

The success of precision oncology—which aims to match the right therapies to the right
patients based on molecular status—is predicated on a robust pipeline of molecular targets …